Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 08, 2022

SELL
$187.54 - $223.02 $76,516 - $90,992
-408 Reduced 19.36%
1,699 $346,000
Q1 2022

May 10, 2022

SELL
$193.77 - $244.14 $159,278 - $200,683
-822 Reduced 28.06%
2,107 $444,000
Q4 2021

Feb 09, 2022

SELL
$223.92 - $287.77 $7,389 - $9,496
-33 Reduced 1.11%
2,929 $703,000
Q3 2021

Nov 12, 2021

SELL
$282.99 - $369.05 $6.17 Million - $8.04 Million
-21,791 Reduced 88.03%
2,962 $838,000
Q2 2021

Aug 10, 2021

SELL
$259.0 - $414.71 $9.43 Million - $15.1 Million
-36,409 Reduced 59.53%
24,753 $8.57 Million
Q1 2021

May 10, 2021

BUY
$242.95 - $284.63 $1.99 Million - $2.33 Million
8,172 Added 15.42%
61,162 $17.1 Million
Q4 2020

Feb 04, 2021

SELL
$236.26 - $355.63 $778,949 - $1.17 Million
-3,297 Reduced 5.86%
52,990 $13 Million
Q3 2020

Nov 10, 2020

BUY
$264.77 - $305.71 $209,433 - $241,816
791 Added 1.43%
56,287 $16 Million
Q2 2020

Aug 07, 2020

BUY
$258.66 - $342.55 $588,192 - $778,958
2,274 Added 4.27%
55,496 $14.8 Million
Q1 2020

May 07, 2020

BUY
$268.85 - $341.04 $28,498 - $36,150
106 Added 0.2%
53,222 $16.8 Million
Q4 2019

Feb 10, 2020

BUY
$220.06 - $304.07 $711,453 - $983,058
3,233 Added 6.48%
53,116 $15.8 Million
Q3 2019

Nov 12, 2019

BUY
$217.44 - $243.88 $10.3 Million - $11.6 Million
47,363 Added 1879.48%
49,883 $11.6 Million
Q2 2019

Aug 14, 2019

BUY
$219.29 - $241.72 $552,610 - $609,134
2,520 New
2,520 $589,000
Q3 2018

Nov 14, 2018

SELL
$293.51 - $383.83 $12,327 - $16,120
-42 Closed
0 $0
Q2 2018

Aug 14, 2018

BUY
$257.52 - $306.91 $10,815 - $12,890
42 New
42 $12,000

Others Institutions Holding BIIB

About BIOGEN INC.


  • Ticker BIIB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 144,000,992
  • Market Cap $20.3B
  • Description
  • Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...
More about BIIB
Track This Portfolio

Track Apriem Advisors Portfolio

Follow Apriem Advisors and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Apriem Advisors, based on Form 13F filings with the SEC.

News

Stay updated on Apriem Advisors with notifications on news.